arrow_back Back Filing freshness 10-Q Q3 FY2025 SEC EDGAR

Clearside Biomedical, Inc.

CLSDQ
— Price unavailable
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
45 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
84
Health
Excellent
Bullish
auto_awesome

Analytical Summary

Clearside Biomedical, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap —
Dividend Yield —
Revenue Growth -80.6% ↘
Op. Margin None
ROIC 13.0% ↗
FCF / Share $-1.05 ↘
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close.

45-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$201.00K
↓ -80.6% —
Net Income Profit after all expenses
$-8.22M
↑ +30.1% —
Operating Margin Operating profit as % of sales
-223.4%
↓ -386.2% —
FCF / Share Free cash flow per share
$-1.05
↑ +12.6% —
Long-Term Debt Long-term obligations
$385.00K
↓ -22.4% —
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Returns
99
Cash Quality →
49

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 12 years · 45 quarters